An Open-Label Study of the Safety and Pharmacokinetics of Repeated-Dose Micafungin in Neonates
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Layout table for eligibility information
Ages Eligible for Study:
up to 120 Days (Child)
Sexes Eligible for Study:
Accepts Healthy Volunteers:
Informed consent and HIPAA authorization of the infant's parent or legally authorized representative must be obtained prior to study entry
Infant has sufficient venous access to permit study drug dosing
Infant is suspected to have a systemic Candida infection and appropriate cultures (blood with or without urine/CSF) are obtained at the time of study entry
Infant has a history of anaphylaxis, hypersensitivity, or any serious reaction to the echinocandin class of antifungals
Infant has received an echinocandin within one month prior to study entry
Infant has a concomitant medical condition which, in the opinion of the investigator and/or medical advisor, may create an unacceptable additional risk
Infant has a life expectancy of less than 96 hours